ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. MindMaze Therapeutics Holding's annualizedNet Income for the quarter that ended in Dec. 2025 was $-12.43 Mil.
MindMaze Therapeutics Holding's average Total Assets over the quarter that ended in Dec. 2025 was $32.38 Mil. Therefore, MindMaze Therapeutics Holding's annualized ROA % for the quarter that ended in Dec. 2025 was -38.39%.
The historical rank and industry rank for MindMaze Therapeutics Holding's ROA % or its related term are showing as below:
RLFTY'
s ROA % Range Over the Past 10 Years
Min: -38.38 Med: -19.73 Max: -1.08
Current: -38.38
During the past 2 years, MindMaze Therapeutics Holding's highest ROA % was -1.08%. The lowest was -38.38%. And the median was -19.73%.
RLFTY's ROA % is ranked worse than 54.37% of 1418
companies
in the Biotechnology industry
Industry Median: -32.87
vs RLFTY: -38.38
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is one times the annual (Dec. 2025) net income data. The Revenue data used here is one times the annual (Dec. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
MindMaze Therapeutics Holding ROA % Related Terms
MindMaze Therapeutics Holding ROA % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MindMaze Therapeutics Holding ROA % Chart
MindMaze Therapeutics Holding Annual Data
Trend
Dec24
Dec25
ROA %
-0.96
-38.39
MindMaze Therapeutics Holding Semi-Annual Data
Dec24
Dec25
ROA %
-0.96
-38.39
RLFTY vs VRTX, REGN, ALNY: ROA % Comparison
For the Biotechnology subindustry, MindMaze Therapeutics Holding's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MindMaze Therapeutics Holding ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MindMaze Therapeutics Holding's ROA % distribution charts can be found below:
* The bar in red indicates where MindMaze Therapeutics Holding's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Dec. 2025) net income data.
ROA % is displayed in the 30-year financial page.
MindMaze Therapeutics Holding (RLFTY) has a ROA % of -38.39% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on MindMaze Therapeutics Holding and its competitors. According to the industry distribution chart, MindMaze Therapeutics Holding ranks #771 out of 1418 companies in the Biotechnology industry, placing it in the top 54.4%.
Is MindMaze Therapeutics Holding's ROA % too high?
MindMaze Therapeutics Holding's current ROA % is -38.39%. Based on the distribution chart, MindMaze Therapeutics Holding ranks #771 out of 1418 companies in the Biotechnology industry, which is below the industry midpoint. Overall, MindMaze Therapeutics Holding has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does MindMaze Therapeutics Holding's ROA % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MindMaze Therapeutics Holding ranks #771 out of 1418 companies for ROA %. This places MindMaze Therapeutics Holding in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on MindMaze Therapeutics Holding and its competitors. MindMaze Therapeutics Holding's current ROA % is -38.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindMaze Therapeutics Holding stock overvalued right now?
MindMaze Therapeutics Holding (RLFTY) has a current ROA % of -38.39%. The current ROA % is -38.39%. MindMaze Therapeutics Holding's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For MindMaze Therapeutics Holding (RLFTY), the current ROA % is -38.39% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
MindMaze Therapeutics Holding Business Description
MindMaze Therapeutics Holding SA is a Swiss-based, commercial-stage biopharmaceutical and neurotechnology company. The company develops and commercializes digital treatments for neurological diseases and brain disorders. Its technology platform integrates software, sensors, and telehealth, and its solutions are used in clinical and home settings internationally. The company has developed evidence-based, next-generation neurotherapeutics that provide evidence-based motor and cognitive treatments to redefine clinical outcomes in patients with neurological disease and brain disorders. The company also manages Relief's existing portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.
11GF Score
Get the complete analysis for RLFTY
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RLFTY has been successfully added to your 